American College of Clinical Pharmacy
      Search      Cart
         

PSAP in JACCP - Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants and Part II: Interactive Case: Rapid Sequence Intubation - 2023 December


Format to Purchase:
Member Price:
$29.95
Nonmember Price:
$29.95

Available for ACPE CREDIT ONLY

 

PSAP in JACCP features are developed from activities presented as part of the Pharmacotherapy Self-Assessment Program (PSAP).

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants
This feature was developed from an interactive case presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).
  • Interactive Case: Click here to access the interactive case.
Disclosures
Consultancies: Emily Owen (Mallinckrodt)
Honoraria: Emily Owen (Mallinckrodt)
Nothing to disclose: Rizah Anwar Assadi, Jenna Goetz

 

Part II: Interactive Case: Rapid Sequence Intubation
This feature was developed from an interactive case presented in PSAP 2023 Book 2 (Critical Care and Emergency Medicine).
  • Interactive Case: Click here to access the case series.
Disclosures
Consultancies: Andrea Boland (Arkansas Association of Hospital Pharmacists)
Grants: Matthew J. Campbell (Spero Therapeutics)
Nothing to disclose: Madeline Jane Foertsch
Release Date: December 08, 2023
BCPS Deadline: June 08, 2024
ACPE Deadline: December 08, 2026

Publication Year: 2023
Format: Online Test

Technical Requirements:

Contents

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

Part II: Interactive Case: Rapid Sequence Intubation

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

Faculty

Emily J. Owen, Pharm.D., MS, BCPS, BCCCP
Critical Care Clinical Pharmacy Specialist and Supervisor
Barnes-Jewish Hospital
Saint Louis, Missouri

Reviewers

Jenna Goetz, Pharm.D., BCPS, BCCCP
Clinical Pharmacy Specialist
Department of Pharmacy
Barnes Jewish Hospital
Saint Louis, Missouri
Rizah Anwar Assadi, Pharm.D., BCPS
Preceptor/Clinical Pharmacist
Ajman
United Arab Emirates

Part II: Interactive Case: Rapid Sequence Intubation

Faculty

Madeline Jane Foertsch, Pharm.D., BCCCP
Clinical Pharmacy Specialist, Neuro-Critical Care
Department of Pharmacy
UC Health – University of Cincinnati Medical Center
Cincinnati, Ohio

Reviewers

Matthew J. Campbell, Pharm.D., BCPS, BCCCP
Emergency Medicine Clinical Coordinator
Emergency Medicine Clinical Pharmacist
PGY2 Emergency Medicine Residency Program Director
Department of Pharmacy
Cleveland Clinic
Cleveland, Ohio
Andrea N. Boland, Pharm.D., BCPS
Clinical Pharmacist
Inpatient Pharmacy
CAVHS
Little Rock, Arkansas

CPE Credit

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience: Pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of critically ill patients in the ICU and emergency department.

Contents

Part I: Interactive Case: Life-threatening Bleeding Caused by Anticoagulants

Activity Number: 0217-0000-23-223-H01-P
Contact Hour(s): 1.50
Activity Type: Application Based
Learning Objectives
  1. Classify antithrombotic agents according to labeled indication, mechanism of action, and pharmacokinetic properties.
  2. Assess life-threatening bleeding events caused by antithrombotic agents for treatment.
  3. Evaluate the risk-benefit of treatments for life-threatening bleeding in the setting of an antithrombotic agent.
  4. Develop an appropriate drug-dose regimen for a patient with life-threatening bleeding associated with an antithrombotic agent.

Part II: Interactive Case: Rapid Sequence Intubation

Activity Number: 0217-0000-23-224-H01-P
Contact Hour(s): 1.50
Activity Type: Application Based
Learning Objectives
  1. Assess the pharmacologic properties and indication or pretreatment agents used in rapid sequence intubation (RSI).
  2. Evaluate the pharmacologic properties of induction agents used in RSI.
  3. Distinguish the pharmacologic properties of neuromuscular blocking agents used in RSI.
  4. Design appropriate patient-specific RSI regimens, and incorporate patient disease state interactions into them.

Commercial Support

The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.